-
Tesofensine: What CNS-Targeting Obesity Research Shows (2026)
Last Updated: May 2026Author: Dr. Alexander Isaacs, Lead Research AdvisorCredentials: Ph.D. in Neuropharmacology, over 15 years analyzing CNS-active compounds and small-molecule metabolic treatments. Investigational Disclaimer: Tesofensine is an investigational small-molecule compound. It has not been approved by the FDA, EMA, or any other regulatory agency for clinical use. Nothing in this article constitutes medical advice,…
-
Vilon Peptide – Immune Benefits, Mechanism & Dosage Guide
FDA Compliance Notice: Vilon is an investigational research compound not approved by the FDA or EMA for human use. For the full legal and medical regulatory disclaimer, please refer to the bottom of this article. TL;DR: Vilon (Lys-Glu) is an ultra-short dipeptide bioregulator derived from thymus research, hypothesized to interact directly with chromatin to modulate…
-
Tirzepatide: Dual Incretin Mechanism and What the Clinical Evidence Shows
Tirzepatide differs from most of the molecules discussed in this section. This is because it is no longer an investigational peptide in a regulatory gray area, but rather an FDA-approved drug marketed under the brand names Mounjaro (for the treatment of type 2 diabetes) and Zepbound (for weight management). It has a completed clinical trial…